Bendiak B, Schachter H
J Biol Chem. 1987 Apr 25;262(12):5784-90.
Purified rat liver UDP-GlcNAc:alpha-D-mannoside beta 1-2 N-acetylglucosaminyltransferase II (Bendiak, B., and Schachter, H. (1987) J. Biol. Chem. 262, 5775-5783) has been characterized kinetically, and its substrate specificity and inhibition characteristics have been determined. Kinetic data indicate an ordered, or largely ordered sequential mechanism, with UDP-GlcNAc binding prior to the acceptor. The minimal acceptor structure required for full activity is: (Formula: see text) The acceptor molecule must have a terminal Man alpha 1-6 residue, and a terminal GlcNAc beta 1-2Man alpha 1-3 branch to display any activity, but does not require the reducing GlcNAc residue, as the enzyme was about 50% as active after reduction of this residue to N-acetylglucosaminitol. Additional residues (Gal beta 1-4 on the GlcNAc beta 1-2Man alpha 1-3 arm, or a bisecting GlcNAc beta 1-4 on the beta-Man residue) abolish catalytic activity. These results suggest a rigid order in the biosynthesis of all N-linked complex oligosaccharides (bisected and nonbisected bi-, tri-, and tetraantennary), since the enzyme must act to completion prior to the action of either UDP-Gal:GlcNAc beta 1-4 galactosyltransferase or N-acetylglucosaminyltransferase III to make such structures. Inhibition studies with nucleotides, sugars, nucleotide-sugars, and their respective analogues revealed that analogues of UDP and UTP, in which the hydrogen at the 5 position of the uracil was substituted with -CH3, bromine, or mercury (as the mercaptide) were good reversible inhibitors of the enzyme, whereas substitution at other sites lessened the inhibitory potency, usually to a large degree.
已对纯化的大鼠肝脏UDP - GlcNAc:α - D - 甘露糖苷β1 - 2 N - 乙酰葡糖胺基转移酶II(本迪亚克,B.,和沙克特,H.(1987年)《生物化学杂志》262,5775 - 5783)进行了动力学表征,并确定了其底物特异性和抑制特性。动力学数据表明这是一种有序的,或很大程度上有序的顺序机制,UDP - GlcNAc在受体之前结合。充分活性所需的最小受体结构为:(公式:见正文)受体分子必须有一个末端Manα1 - 6残基,以及一个末端GlcNAcβ1 - 2Manα1 - 3分支才能显示任何活性,但不需要还原端的GlcNAc残基,因为将该残基还原为N - 乙酰葡糖胺醇后,酶的活性约为原来的50%。其他残基(GlcNAcβ1 - 2Manα1 - 3臂上的Galβ1 - 4,或β - Man残基上的平分GlcNAcβ1 - 4)会消除催化活性。这些结果表明,在所有N - 连接的复合寡糖(平分和未平分的二、三、四天线型)的生物合成中存在严格的顺序,因为在UDP - Gal:GlcNAcβ1 - 4半乳糖基转移酶或N - 乙酰葡糖胺基转移酶III作用以形成此类结构之前,该酶必须先作用完成。用核苷酸、糖类、核苷酸糖及其各自类似物进行的抑制研究表明,尿嘧啶5位氢被 - CH3、溴或汞(作为硫醇盐)取代的UDP和UTP类似物是该酶的良好可逆抑制剂,而在其他位点取代会降低抑制效力,通常会大幅降低。